

## SUPPLEMENTARY TABLES

**Supplementary Table 4. Primer sequence used in this study.**

Name	Direction	Primer(5'-3')
MAFG-AS1	Forward	5'-CGGGAGGAAGATAAACGGGG-3'
	Reverse	5'-TGACCACGGAACACCTTCAG-3'
miR-339-5p	Forward	5'-GGGTCCCTGTCCTCCA-3'
	Reverse	5'-GCCTGAGATGAAGCACGTG-3'
CDK2	Forward	5'-CCAGGAGTTACTTCTATGCCTGA-3'
	Reverse	5'-TTCATCCAGGGGAGGTACAAC-3'
ESR1	Forward	5'-CCGGCTCCGCAAATGCTACGA-3'
	Reverse	5'-AGCGGGCTTGGCCAAAGGTT-3'
U6	Forward	5'-GCTTCGGCAGCACATATACTAAAAT-3'
	Reverse	5'-CGCTTACGAATTTGCGTGTTCAT-3'
18S	Forward	5'-CCCGGGGAGGTAGTGACGAAAAAT-3'
	Reverse	5'-CGCCCGCCGCTCCCAAGAT-3'

**Supplementary Table 5. siRNA sequences used in this study.**

Name	Sequences (5'-3')
si-MAFG-AS1-1	5'-UCCUGAGAGCAGCAGAUCUTT-3'
si-MAFG-AS1-2	5'-GGAGUCAGGGCAAUCCAATT-3'
si-MAFG-AS1-3	5'-GGUAACAUAGAGACCCUAUTT-3'
si-ESR1-1	5'-GGAGAAUGUUGAAACACAATT-3'
si-ESR1-2	5'-GGAUUUGACCCUCCAUGAUTT-3'
si-ESR1-3	5'-GGGCUCUACUUCAUCGCAUTT-3'
si-CDK2-1	5'-CGGAGCUUGUUAUCGCAAATT-3'
si-CDK2-2	5'-GAGUCCUGUUCGUACUUATT-3'
si-CDK2-3	5'-CAAGAUCUCAAGAAAUUCATT-3'
si-NC	5'-AATTCTCCGAACGTGTCACGT-3'